Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 781

1.

A clinical and molecular Phase II trial of oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): A study of the Princess Margaret Phase II Consortium.

Lheureux S, Tinker AV, Clarke BA, Ghatage P, Welch S, Weberpals JI, Dhani NC, Butler MO, Tonkin K, Tan Q, Tan DSP, Brooks K, Ramsahai J, Wang L, Pham NA, Shaw PA, Tsao MS, Garg S, Stockley TL, Oza AM.

Clin Cancer Res. 2018 Aug 14. pii: clincanres.1244.2018. doi: 10.1158/1078-0432.CCR-18-1244. [Epub ahead of print]

PMID:
30108107
2.

Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.

Devarakonda S, Rotolo F, Tsao MS, Lanc I, Brambilla E, Masood A, Olaussen KA, Fulton R, Sakashita S, McLeer-Florin A, Ding K, Le Teuff G, Shepherd FA, Pignon JP, Graziano SL, Kratzke R, Soria JC, Seymour L, Govindan R, Michiels S.

J Clin Oncol. 2018 Aug 14:JCO2018781963. doi: 10.1200/JCO.2018.78.1963. [Epub ahead of print]

PMID:
30106638
3.

Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk.

Ji X, Bossé Y, Landi MT, Gui J, Xiao X, Qian D, Joubert P, Lamontagne M, Li Y, Gorlov I, de Biasi M, Han Y, Gorlova O, Hung RJ, Wu X, McKay J, Zong X, Carreras-Torres R, Christiani DC, Caporaso N, Johansson M, Liu G, Bojesen SE, Le Marchand L, Albanes D, Bickeböller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Chen C, Teare MD, Field JK, Kiemeney LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Shen H, Hong YC, Yuan JM, Bertazzi PA, Pesatori AC, Ye Y, Diao N, Su L, Zhang R, Brhane Y, Leighl N, Johansen JS, Mellemgaard A, Saliba W, Haiman C, Wilkens L, Fernandez-Somoano A, Fernandez-Tardon G, van der Heijden EHFM, Kim JH, Dai J, Hu Z, Davies MPA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Doherty J, Goodman GE, Cox A, Taylor F, Woll P, Brüske I, Manz J, Muley T, Risch A, Rosenberger A, Grankvist K, Johansson M, Shepherd F, Tsao MS, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orlowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Zienolddiny S, Duell EJ, Butler LM, Koh WP, Gao YT, Houlston R, McLaughlin J, Stevens V, Nickle DC, Obeidat M, Timens W, Zhu B, Song L, Artigas MS, Tobin MD, Wain LV, Gu F, Byun J, Kamal A, Zhu D, Tyndale RF, Wei WQ, Chanock S, Brennan P, Amos CI.

Nat Commun. 2018 Aug 13;9(1):3221. doi: 10.1038/s41467-018-05074-y.

PMID:
30104567
4.

Targeting the CDK4/6-Rb pathway enhances response to PI3K inhibition in PIK3CA mutant lung squamous cell carcinoma.

Shi R, Li M, Raghavan V, Tam S, Cabanero M, Pham NA, Shepherd FA, Moghal N, Tsao MS.

Clin Cancer Res. 2018 Aug 9. pii: clincanres.0717.2018. doi: 10.1158/1078-0432.CCR-18-0717. [Epub ahead of print]

PMID:
30093452
5.

The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.

Jao K, Tomasini P, Kamel-Reid S, Korpanty GJ, Mascaux C, Sakashita S, Labbé C, Leighl NB, Liu G, Feld R, Bradbury PA, Hwang DM, Pintilie M, Tsao MS, Shepherd FA.

Lung Cancer. 2018 Sep;123:22-29. doi: 10.1016/j.lungcan.2018.06.023. Epub 2018 Jun 19.

PMID:
30089591
6.

Pyr3 Induces Apoptosis and Inhibits Migration in Human Glioblastoma Cells.

Chang HH, Cheng YC, Tsai WC, Tsao MJ, Chen Y.

Cell Physiol Biochem. 2018 Aug 3;48(4):1694-1702. doi: 10.1159/000492293. [Epub ahead of print]

7.

Successful management of perivascular epithelioid cell tumor of the rectum with recurrent liver metastases: A case report.

Lin KH, Chang NJ, Liou LR, Su MS, Tsao MJ, Huang ML.

Medicine (Baltimore). 2018 Aug;97(31):e11679. doi: 10.1097/MD.0000000000011679.

8.

Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer.

Rotolo F, Zhu CQ, Brambilla E, Graziano SL, Olaussen K, Le-Chevalier T, Pignon JP, Kratzke R, Soria JC, Shepherd FA, Seymour L, Michiels S, Tsao MS.

Transl Lung Cancer Res. 2018 Jun;7(3):416-427. doi: 10.21037/tlcr.2018.05.01.

9.

Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19.

Hua JT, Ahmed M, Guo H, Zhang Y, Chen S, Soares F, Lu J, Zhou S, Wang M, Li H, Larson NB, McDonnell SK, Patel PS, Liang Y, Yao CQ, van der Kwast T, Lupien M, Feng FY, Zoubeidi A, Tsao MS, Thibodeau SN, Boutros PC, He HH.

Cell. 2018 Jul 26;174(3):564-575.e18. doi: 10.1016/j.cell.2018.06.014. Epub 2018 Jul 19.

PMID:
30033362
10.

Importance of Long-term Low-Dose CT Follow-up after Negative Findings at Previous Lung Cancer Screening.

Kavanagh J, Liu G, Menezes R, O'Kane GM, McGregor M, Tsao M, Shepherd FA, Schmidt H.

Radiology. 2018 Jul 10:180053. doi: 10.1148/radiol.2018180053. [Epub ahead of print]

PMID:
29989522
11.

Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective.

Ionescu DN, Downes MR, Christofides A, Tsao MS.

Curr Oncol. 2018 Jun;25(3):e209-e216. doi: 10.3747/co.25.4031. Epub 2018 Jun 28. Review.

12.

Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer.

Cabanero M, Tsao MS.

Curr Oncol. 2018 Jun;25(Suppl 1):S38-S44. doi: 10.3747/co.25.3761. Epub 2018 Jun 13. Review.

13.

Lung cancer in never smokers from the Princess Margaret Cancer Centre.

Korpanty GJ, Kamel-Reid S, Pintilie M, Hwang DM, Zer A, Liu G, Leighl NB, Feld R, Siu LL, Bedard PL, Tsao MS, Shepherd FA.

Oncotarget. 2018 Apr 27;9(32):22559-22570. doi: 10.18632/oncotarget.25176. eCollection 2018 Apr 27.

14.

Impact of radiation-induced nausea and vomiting on quality of life.

Yee C, Drost L, Zhang L, Wan BA, Ganesh V, Tsao M, Barnes E, Pasetka M, DeAngelis C, Chow E.

Support Care Cancer. 2018 May 28. doi: 10.1007/s00520-018-4286-y. [Epub ahead of print]

PMID:
29808378
15.

PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.

Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, Bubendorf L, Chirieac L, Chen G, Chou TY, Chung JH, Dacic S, Lantuejoul S, Mino-Kenudson M, Moreira AL, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Russell PA, Sauter J, Thunnissen E, Wistuba I, Yu H, Wynes MW, Pintilie M, Yatabe Y, Hirsch FR.

J Thorac Oncol. 2018 May 22. pii: S1556-0864(18)30626-9. doi: 10.1016/j.jtho.2018.05.013. [Epub ahead of print]

PMID:
29800747
16.

Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis.

Chow R, Warr DG, Navari RM, Tsao M, Popovic M, Chiu L, Milakovic M, Lam H, DeAngelis C.

Support Care Cancer. 2018 Aug;26(8):2519-2549. doi: 10.1007/s00520-018-4237-7. Epub 2018 May 23. Review.

PMID:
29796708
17.

Magnolol Inhibits Human Glioblastoma Cell Migration by Regulating N-Cadherin.

Cheng YC, Tsao MJ, Chiu CY, Kan PC, Chen Y.

J Neuropathol Exp Neurol. 2018 Jun 1;77(6):426-436. doi: 10.1093/jnen/nly021.

PMID:
29788114
19.

A pilot study with palonosetron in the prophylaxis of radiation-induced nausea and vomiting.

Ganesh V, Drost L, DeAngelis C, Wan BA, Pasetka M, Chan S, Zhang L, Tsao M, Barnes E, Pulenzas N, Chung H, Zaki P, Yee C, Chow E.

Ann Palliat Med. 2018 Apr;7(2):211-220. doi: 10.21037/apm.2018.03.12.

20.

Symptom clusters using the EORTC QLQ-C15-PAL in palliative radiotherapy.

Ganesh V, Zhang L, Wan BA, Drost L, Tsao M, Barnes E, DeAngelis C, Chung H, Diaz P, Chow E.

Ann Palliat Med. 2018 Apr;7(2):192-204. doi: 10.21037/apm.2017.12.03.

21.

The eighth TNM classification for lung cancer-What is next?

Tsao MS, Yoon JY.

Lung Cancer. 2018 Jul;121:97-98. doi: 10.1016/j.lungcan.2018.04.018. Epub 2018 Apr 25. No abstract available.

PMID:
29724454
22.

New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.

Galateau Salle F, Le Stang N, Nicholson AG, Pissaloux D, Churg A, Klebe S, Roggli VL, Tazelaar HD, Vignaud JM, Attanoos R, Beasley MB, Begueret H, Capron F, Chirieac L, Copin MC, Dacic S, Danel C, Foulet-Roge A, Gibbs A, Giusiano-Courcambeck S, Hiroshima K, Hofman V, Husain AN, Kerr K, Marchevsky A, Nabeshima K, Picquenot JM, Rouquette I, Sagan C, Sauter JL, Thivolet F, Travis WD, Tsao MS, Weynand B, Damiola F, Scherpereel A, Pairon JC, Lantuejoul S, Rusch V, Girard N.

J Thorac Oncol. 2018 Aug;13(8):1189-1203. doi: 10.1016/j.jtho.2018.04.023. Epub 2018 Apr 30.

PMID:
29723687
23.

Evidence-based best practices for EGFR T790M testing in lung cancer in Canada.

Stockley T, Souza CA, Cheema PK, Melosky B, Kamel-Reid S, Tsao MS, Spatz A, Karsan A.

Curr Oncol. 2018 Apr;25(2):163-169. doi: 10.3747/co.25.4044. Epub 2018 Apr 30.

24.

Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC).

Dhont L, Pintilie M, Kaufman E, Navab R, Tam S, Burny A, Shepherd F, Belayew A, Tsao MS, Mascaux C.

BMC Cancer. 2018 Apr 16;18(1):429. doi: 10.1186/s12885-018-4215-y.

25.

A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.

Jonker DJ, Tang PA, Kennecke H, Welch SA, Cripps MC, Asmis T, Chalchal H, Tomiak A, Lim H, Ko YJ, Chen EX, Alcindor T, Goffin JR, Korpanty GJ, Feilotter H, Tsao MS, Theis A, Tu D, Seymour L.

Clin Colorectal Cancer. 2018 Mar 8. pii: S1533-0028(17)30462-0. doi: 10.1016/j.clcc.2018.03.001. [Epub ahead of print]

PMID:
29653857
26.

Targeting DTL induces cell cycle arrest and senescence and suppresses cell growth and colony formation through TPX2 inhibition in human hepatocellular carcinoma cells.

Chen YC, Chen IS, Huang GJ, Kang CH, Wang KC, Tsao MJ, Pan HW.

Onco Targets Ther. 2018 Mar 21;11:1601-1616. doi: 10.2147/OTT.S147453. eCollection 2018.

27.

Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC.

Melosky B, Chu Q, Juergens RA, Leighl N, Ionescu D, Tsao MS, McLeod D, Hirsh V.

Cancer Treat Rev. 2018 Apr;65:65-77. doi: 10.1016/j.ctrv.2018.02.005. Epub 2018 Feb 22. Review.

PMID:
29567557
28.

Multiplexed Real-Time NMR GTPase Assay for Simultaneous Monitoring of Multiple Guanine Nucleotide Exchange Factor Activities from Human Cancer Cells and Organoids.

Gebregiworgis T, Marshall CB, Nishikawa T, Radulovich N, Sandí MJ, Fang Z, Rottapel R, Tsao MS, Ikura M.

J Am Chem Soc. 2018 Apr 4;140(13):4473-4476. doi: 10.1021/jacs.7b13703. Epub 2018 Mar 22.

PMID:
29543440
29.

Translation of Knowledge to Practice-Improving Awareness in NSCLC Molecular Testing.

Zer A, Cutz JC, Sekhon H, Hwang DM, Sit C, Maganti M, Sung M, Binnie M, Brade A, Chung TB, Kamel-Reid S, Paul N, Tsao MS, Waddell T, da Cunha Santos G, Patel M, Carter RF, Leighl NB.

J Thorac Oncol. 2018 Jul;13(7):1004-1011. doi: 10.1016/j.jtho.2018.03.005. Epub 2018 Mar 11.

PMID:
29535011
30.

Genomic Testing in Lung Cancer: Past, Present, and Future.

Mascaux C, Tsao MS, Hirsch FR.

J Natl Compr Canc Netw. 2018 Mar;16(3):323-334. doi: 10.6004/jnccn.2017.7019. Review.

PMID:
29523671
31.

Correction to: Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections.

Yoshimoto M, Ludkovski O, Good J, Pereira C, Gooding RJ, McGowan-Jordan J, Boag A, Evans A, Tsao MS, Nuin P, Squire JA.

Lab Invest. 2018 Jun;98(6):839. doi: 10.1038/s41374-018-0037-4.

PMID:
29520053
32.

Differentially expressed microRNAs in lung adenocarcinoma invert effects of copy number aberrations of prognostic genes.

Tokar T, Pastrello C, Ramnarine VR, Zhu CQ, Craddock KJ, Pikor LA, Vucic EA, Vary S, Shepherd FA, Tsao MS, Lam WL, Jurisica I.

Oncotarget. 2018 Jan 8;9(10):9137-9155. doi: 10.18632/oncotarget.24070. eCollection 2018 Feb 6.

33.

Standardizing biomarker testing for Canadian patients with advanced lung cancer.

Melosky B, Blais N, Cheema P, Couture C, Juergens R, Kamel-Reid S, Tsao MS, Wheatley-Price P, Xu Z, Ionescu DN.

Curr Oncol. 2018 Feb;25(1):73-82. doi: 10.3747/co.25.3867. Epub 2018 Feb 28.

34.

Efficacy of Prophylactic Radiotherapy in the Treatment of Heterotopic Ossification.

Tao MJ, Probyn L, Drost L, Kreder H, Nousiainen M, Tsao M, Barnes E, Jenkinson R, Wan BA, Poon M, Chan S, Chow E.

Clin Oncol (R Coll Radiol). 2018 Jun;30(6):393-395. doi: 10.1016/j.clon.2018.02.028. Epub 2018 Mar 2. No abstract available.

PMID:
29499879
35.

Eighth Edition Staging of Thoracic Malignancies: Implications for the Reporting Pathologist.

Nicholson AG, Tsao MS, Travis WD, Patil DT, Galateau-Salle F, Marino M, Dacic S, Beasley MB, Butnor KJ, Yatabe Y, Pass HI, Rusch VW, Detterbeck FC, Asamura H, Rice TW, Rami-Porta R.

Arch Pathol Lab Med. 2018 May;142(5):645-661. doi: 10.5858/arpa.2017-0245-RA. Epub 2018 Feb 26.

PMID:
29480761
36.

Extracellular ATP is Differentially Metabolized on Papillary Thyroid Carcinoma Cells Surface in Comparison to Normal Cells.

Bertoni APS, de Campos RP, Tsao M, Braganhol E, Furlanetto TW, Wink MR.

Cancer Microenviron. 2018 Jun;11(1):61-70. doi: 10.1007/s12307-018-0206-4. Epub 2018 Feb 17.

37.

Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly.

Costantini A, Grynovska M, Lucibello F, Moisés J, Pagès F, Tsao MS, Shepherd FA, Bouchaab H, Garassino M, Aerts JGJV, Mazières J, Mondini M, Berghmans T, Meert AP, Cadranel J.

Eur Respir J. 2018 Feb 14;51(2). pii: 1702072. doi: 10.1183/13993003.02072-2017. Print 2018 Feb.

PMID:
29444918
38.

The Integrated Genomic Landscape of Thymic Epithelial Tumors.

Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde AM, Kim J, Leiserson MDM, Sethi G, Lu C, Ryan M, Su X, Cherniack AD, Robertson G, Akbani R, Spellman P, Weinstein JN, Hayes DN, Raphael B, Lichtenberg T, Leraas K, Zenklusen JC; Cancer Genome Atlas Network, Fujimoto J, Scapulatempo-Neto C, Moreira AL, Hwang D, Huang J, Marino M, Korst R, Giaccone G, Gokmen-Polar Y, Badve S, Rajan A, Ströbel P, Girard N, Tsao MS, Marx A, Tsao AS, Loehrer PJ.

Cancer Cell. 2018 Feb 12;33(2):244-258.e10. doi: 10.1016/j.ccell.2018.01.003.

PMID:
29438696
39.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y.

J Mol Diagn. 2018 Mar;20(2):129-159. doi: 10.1016/j.jmoldx.2017.11.004. Epub 2018 Jan 23.

PMID:
29398453
40.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y.

J Thorac Oncol. 2018 Mar;13(3):323-358. doi: 10.1016/j.jtho.2017.12.001. Epub 2018 Jan 25.

PMID:
29396253
41.

Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.

Tsao MN, Xu W, Wong RK, Lloyd N, Laperriere N, Sahgal A, Rakovitch E, Chow E.

Cochrane Database Syst Rev. 2018 Jan 25;1:CD003869. doi: 10.1002/14651858.CD003869.pub4. Review.

PMID:
29365347
42.

To frame or not to frame? Cone-beam CT-based analysis of head immobilization devices specific to linac-based stereotactic radiosurgery and radiotherapy.

Babic S, Lee Y, Ruschin M, Lochray F, Lightstone A, Atenafu E, Phan N, Mainprize T, Tsao M, Soliman H, Sahgal A.

J Appl Clin Med Phys. 2018 Mar;19(2):111-120. doi: 10.1002/acm2.12251. Epub 2018 Jan 24.

43.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y.

Arch Pathol Lab Med. 2018 Mar;142(3):321-346. doi: 10.5858/arpa.2017-0388-CP. Epub 2018 Jan 22.

PMID:
29355391
44.

Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections.

Yoshimoto M, Ludkovski O, Good J, Pereira C, Gooding RJ, McGowan-Jordan J, Boag A, Evans A, Tsao MS, Nuin P, Squire JA.

Lab Invest. 2018 Apr;98(4):403-413. doi: 10.1038/s41374-017-0007-2. Epub 2018 Jan 16. Review. Erratum in: Lab Invest. 2018 Mar 8;:.

PMID:
29339834
45.

Stereotactic radiosurgery for vestibular schwannoma: International Stereotactic Radiosurgery Society (ISRS) Practice Guideline.

Tsao MN, Sahgal A, Xu W, De Salles A, Hayashi M, Levivier M, Ma L, Martinez R, Régis J, Ryu S, Slotman BJ, Paddick I.

J Radiosurg SBRT. 2017;5(1):5-24.

46.

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib.

Cheema PK, Doherty M, Tsao MS.

J Thorac Oncol. 2017 Dec;12(12):e200-e202. doi: 10.1016/j.jtho.2017.07.033. No abstract available.

PMID:
29169524
47.

Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts.

Brana I, Pham NA, Kim L, Sakashita S, Li M, Ng C, Wang Y, Loparco P, Sierra R, Wang L, Clarke BA, Neel BG, Siu LL, Tsao MS.

Oncotarget. 2017 Jul 8;8(49):84659-84670. doi: 10.18632/oncotarget.19109. eCollection 2017 Oct 17.

48.

Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience.

Chiu JW, Krzyzanowska MK, Serra S, Knox JJ, Dhani NC, Mackay H, Hedley D, Moore M, Liu G, Burkes RL, Brezden-Masley C, Roehrl MH, Craddock KJ, Tsao MS, Zhang T, Yu C, Kamel-Reid S, Siu LL, Bedard PL, Chen EX.

Clin Colorectal Cancer. 2018 Mar;17(1):73-79. doi: 10.1016/j.clcc.2017.10.010. Epub 2017 Oct 23.

PMID:
29128266
49.

Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung.

Nicholson AG, Torkko K, Viola P, Duhig E, Geisinger K, Borczuk AC, Hiroshima K, Tsao MS, Warth A, Lantuejoul S, Russell PA, Thunnissen E, Marchevsky A, Mino-Kenudson M, Beasley MB, Botling J, Dacic S, Yatabe Y, Noguchi M, Travis WD, Kerr K, Hirsch FR, Chirieac LR, Wistuba II, Moreira A, Chung JH, Chou TY, Bubendorf L, Chen G, Pelosi G, Poleri C, Detterbeck FC, Franklin WA.

J Thorac Oncol. 2018 Feb;13(2):205-217. doi: 10.1016/j.jtho.2017.10.019. Epub 2017 Nov 7.

PMID:
29127023
50.

Development and Internal Validation of a Clinical Risk Score to Predict Pain Response After Palliative Radiation Therapy in Patients With Bone Metastases.

van der Velden JM, Peters M, Verlaan JJ, Versteeg AL, Zhang L, Tsao M, Danjoux C, Barnes E, van Vulpen M, Chow E, Verkooijen HM.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):859-866. doi: 10.1016/j.ijrobp.2017.07.029. Epub 2017 Jul 31.

PMID:
29063851

Supplemental Content

Support Center